Evidence supporting the use of: Phytocannabinoid (unspecified)
For the health condition: Addictions (drugs)

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phytocannabinoids, primarily cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), have been explored in modern research for their potential to support the treatment of drug addictions. Preclinical studies and some early clinical trials suggest that CBD may have a modulatory effect on craving and withdrawal symptoms associated with substances such as opioids, cocaine, and tobacco. For example, a randomized, double-blind, placebo-controlled study published in 2019 found that CBD reduced cue-induced craving and anxiety in individuals with heroin use disorder. Other small-scale clinical trials and animal studies have suggested that phytocannabinoids may influence reward pathways and stress response systems involved in addiction.

However, the overall evidence base is still limited, with small sample sizes, short study durations, and mixed results. Most studies focus on CBD rather than the full spectrum of phytocannabinoids. There is insufficient high-quality, long-term clinical data to firmly establish efficacy or safety. As such, while the use of phytocannabinoids for addiction is a subject of scientific inquiry and shows some potential, it cannot currently be considered an evidence-based standard treatment. Ongoing research is needed to clarify their role, optimal dosing, and potential risks. Thus, the evidence is rated as 2 out of 5, reflecting preliminary but not conclusive scientific support.

More about Phytocannabinoid (unspecified)
More about Addictions (drugs)

Products containing Phytocannabinoid (unspecified)

We currently have no products on Vitabase that contain this ingredient.